WHO世界卫生组织：2025年关于奈韦拉用于HIV预防的指南及长效注射暴露前预防的检测策略报告（英文版）

Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acq